靶向cd70的CAR-T/NK疗法：原理、进展和未来方向

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-10-02 DOI:10.1016/j.tranon.2025.102555

Sijia Yan, Xiaojian Zhu, Yi Xiao

{"title":"靶向cd70的CAR-T/NK疗法：原理、进展和未来方向","authors":"Sijia Yan, Xiaojian Zhu, Yi Xiao","doi":"10.1016/j.tranon.2025.102555","DOIUrl":null,"url":null,"abstract":"<div><div>Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases. CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"62 ","pages":"Article 102555"},"PeriodicalIF":5.0000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions\",\"authors\":\"Sijia Yan, Xiaojian Zhu, Yi Xiao\",\"doi\":\"10.1016/j.tranon.2025.102555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases. CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.</div></div>\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"62 \",\"pages\":\"Article 102555\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523325002864\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325002864","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体T和自然杀伤（CAR-T/NK）细胞是一种快速发展的细胞免疫治疗技术，在血液病的治疗中取得了巨大的成就。CD70作为一种表面抗原，在多种血液恶性肿瘤（包括急性髓系白血病、非霍奇金淋巴瘤、多发性骨髓瘤等）和实体肿瘤（如肾细胞癌、骨肉瘤、胶质瘤）的肿瘤细胞上表达，是CAR-T/NK细胞的潜在靶点。目前，针对CD70的CAR-T/NK细胞的多项临床前研究和临床试验正在进行中，为治疗CD70阳性肿瘤带来了新的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions

查看原文本刊更多论文

CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions

Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases. CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.